Pricing Log in Create free account
Friday 6 November 2026 Export ASND’s income statement to Excel — free account

Ascendis Pharma A/S

ASND Healthcare Biotechnology

Ascendis Pharma A/S’s revenue for fiscal 2025 (year ended December 2025) was $814.8 million, up 107.1% from fiscal 2024.

Revenue
+119.9%
EPS
+612.3%
Free cash flow
+2,335.9%
Total debt
−41.8%

Quarter to June 2026, against a year earlier

254.99 1.54 +0.61%
Market cap
$16.6B
P/E
18.3×
Fwd P/E
15.4×
Dividend yield
—
F-score
5/9
Altman Z
2.02
Beneish M
−2.51
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Ascendis Pharma A/S (ASND) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, Ascendis Pharma A/S (ASND) trades at a EV/Sales of 13.1×. Over the past ten years it has ranged from 0.0× (September 2015) to 6,182× (October 2018); the current reading is higher than 8% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 16.2× (23.04%)
FY2024 21.1× (17.09%)
FY2023 25.4× (79.02%)
FY2022 121× (83.32%)
FY2021 726× (25.44%)
FY2020 974× 149.69%
FY2019 390× 116.97%
FY2018 180× (72.19%)
FY2017 646× 900.06%
FY2016 64.6× 92.52%

Quarterly newest first

Period EV/Sales Change
Jun 2026 13.8× (4.95%)
Mar 2026 14.5× (10.40%)
Dec 2025 16.2× (5.51%)
Sep 2025 17.2× (14.55%)
42 more quarters

Against its own ten years

Low 0.0× High 6,182×
Ten-year median 115×
Current reading's percentile 2

EV/Sales against peers

Company EV/Sales
BNTX BioNTech SE Sponsored ADR compare 1.8×
ALNY Alnylam Pharmaceuticals, Inc. compare 3.7×
JAZZ Jazz Pharmaceuticals PLC compare 3.7×
EXEL Exelixis, Inc. compare 6.5×
HALO Halozyme Therapeutics, Inc. compare 9.0×
ASND Ascendis Pharma A/S 13.1×
INSM Insmed, Inc. compare 15.4×
BBIO BridgeBio Pharma, Inc. compare 15.9×
SMMT Summit Therapeutics PLC compare 15,046×
Biotechnology industry median 9.0×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on ASND